Sleep Apnea - Pipeline Review, H1 2016

  • ID: 3665222
  • Report
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Galleon Pharmaceuticals
  • Vivus, Inc.
  • MORE
Sleep Apnea - Pipeline Review, H1 2016

Summary

‘Sleep Apnea - Pipeline Review, H1 2016’, provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
- The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
- The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Galleon Pharmaceuticals
  • Vivus, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Sleep Apnea Overview

Therapeutics Development

Pipeline Products for Sleep Apnea - Overview

Pipeline Products for Sleep Apnea - Comparative Analysis

Sleep Apnea - Therapeutics under Development by Companies

Sleep Apnea - Therapeutics under Investigation by Universities/Institutes

Sleep Apnea - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Sleep Apnea - Products under Development by Companies

Sleep Apnea - Products under Investigation by Universities/Institutes

Sleep Apnea - Companies Involved in Therapeutics Development

Galleon Pharmaceuticals

RespireRx Pharmaceuticals Inc.

SK Biopharmaceuticals Co., Ltd.

Vivus, Inc.

Sleep Apnea - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(phentermine + topiramate) ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CX-1739 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dexloxiglumide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GAL-475 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GAL-475 Backups - Drug Profile

Product Description

Mechanism of Action

R&D Progress

itriglumide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SKL-N05 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Sleep Apnea - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sleep Apnea - Recent Pipeline Updates

Sleep Apnea - Dormant Projects

Sleep Apnea - Discontinued Products

Sleep Apnea - Product Development Milestones

Featured News & Press Releases

Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016

Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA

May 14, 2015: VIVUS Announces Scientific Presentations

May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders

May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists

Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies

Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules

Jan 09, 2012: VIVUS Provides Update on Regulatory Status Of Qnexa

Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sleep Apnea, H1 2016

Number of Products under Development for Sleep Apnea - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H1 2016

Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H1 2016

Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Sleep Apnea - Pipeline by Vivus, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Sleep Apnea Therapeutics - Recent Pipeline Updates, H1 2016

Sleep Apnea - Dormant Projects, H1 2016

Sleep Apnea - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Sleep Apnea, H1 2016

Number of Products under Development for Sleep Apnea - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Galleon Pharmaceuticals
RespireRx Pharmaceuticals Inc.
SK Biopharmaceuticals Co., Ltd.
Vivus, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll